All News

shoulder.exam_.jpg

ACR21 Previews from Creaky Joints

d Jack Cush, MD

CreakyJoints will present 11 posters and two oral presentations at ACR 2021. COVID-19 research revealed significantly high levels of anxiety, anger, depression, and social isolation, which were linked to medication interruptions and associated flares suggesting during the pandemic, patients often felt unsupported by all levels of the healthcare system. 

Read Article
Michael Brenner, Basic Science Year in review: Auto-antibodies against interferon, present prior to COVID-19, mostly in men and increases with age: increases risk to #COVID19 mortality #ACR21 @RheumNow https://t.co/5sFqcBtStD
Eric Dein ericdeinmd ( View Tweet)
OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA vector giving immunetolerance in mouse model of encephalitis. #ACRBest Yr in Review by M Brenner discussion of paper. Double edged sword ⚔️ @RheumNow #ACR21 https://t.co/8sRl351D27
Janet Pope Janetbirdope ( View Tweet)
Join us tomorrow at #ACR21 in the #COVID19 hub at 12p EST where I’ll be discussing outpatient management of high risk covid patients with @LCalabreseDO #mAbs @philipcrobinson @ACRheum https://t.co/LkSw48cnWw
Cassandra Calabrese CCalabreseDO ( View Tweet)
#ACR21 Anti-IFN autoantibodies predisposing patients to severe COVID ...🤔 And can be done with quantiferon test! https://t.co/n3h4vpQGdR
LiSa ◡̈︎ rheumarhyme ( View Tweet)
Telemedicine black computer

Negative Concerns of Telemedicine in Rheumatology

d Jack Cush, MD

Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.

Read Article
vaccine.jpg

Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose

d ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a t

Read Article
RheumNow Podcast square

RheumNow Podcast – Like Father, Like Daughter (10.29.2021)

d Jack Cush, MD

Bad things happen when our patients go into the ICU and it's not always due to the disease. Good things happen when we rise from sitting. And guess what? Rheumatologists are setting cardiology straight about hydroxychloroquine and chloroquine. This, and a special recognition of parent-child rheumatologists, along with the news and articles from this week on RheumNow.

Read Article
MMWR reports those who have recv COVID-19 vaccine have lower risk non–COVID-19 mortality (vs unvaccinated). Adjusted rel risk of non–COVID-19 death for Pfizer-vaccine (2 doses RR 0.34), Moderna (0.31), Janssen (0.54). NO INCR MORTAL RISK IN VACCINATED https://t.co/X6X1w1aYoU

Links:

Dr. John Cush RheumNow ( View Tweet)

New Download Available! FDA EUA for Baricitinib in COVID https://t.co/yTQLb7DDvR https://t.co/n9Npg0Pq5q

Links:

Dr. John Cush RheumNow ( View Tweet)
From March to Dec 2020, study of 116K COVID pts saw monthly rates of hospitalization (105/100K), ICU admits (20/100K), & death (12/100K) -peaked 12/20. Highest w/ age >65yrs, hispanics, blacks. Remdesivir incr 1.7% to 54%; Steroids 19% to 74.2% https://t.co/5pzu74YIz6

Links:

Dr. John Cush RheumNow ( View Tweet)

syringe,needle,vaccine

How Should Patients With Autoimmune Diseases Approach COVID Vaccination?

d MedPage Today

Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.

Read Article
Israeli study of 1497 fully vaccinated health care workers finds 39 (2.4% Breakthrough COVID infections (Jan-May 2021), most cases were mild or asymptomatic, 19% w/ persistent Sxs (>6 ws); infected had lower neutralizing Abs. https://t.co/deYTVLRQCU

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)

d Jack Cush, MD

Today I have a few questions: Is tramadol really a weak narcotic? Should we really still be doing placebo-controlled trials? What are we going to do about our patients who are smokers? This and more, in this week's review of the news and journal articles.

Read Article
RECOVERY study of hospitalized COVID-19 pts compared colchicine to PBO (+usual care). Colchicine had no effect on 28d mortality (21% vs 21%), time to D/C(10 d vs 10d), LIve D/C (70 vs 70%), mechanical vent or death (25 vs 25%) https://t.co/dYZglKzwxC

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA reports the COVID-19 combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% By May 2021, there were 2.1 SARS-CoV-2 infections per reported COVID-19 case. https://t.co/bUZ5AqYnxM

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID Test Antibody

Is It OK to Continue TNF Inhibitors with COVID-19 Infection?

d Jack Cush, MD

Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).

Read Article
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC. Read more on #RheumNow https://t.co/Q422Sl5Csj

Links:

Dr. John Cush RheumNow ( View Tweet)

In case you missed it… Still’s Disease Following COVID-19 Vaccination Read more on #RheumNow https://t.co/23R41Pydve https://t.co/a44cYIkc98

Links:

Dr. John Cush RheumNow ( View Tweet)
For best practices in managing the Delta wave, the US would have done well to consult Puerto Rico US 26 cases/100,000 people, 19/100K hospitalized 57% vaccinated PR 3 cases/100,000 people, 3/100K hospitalized, 68% vaccinated https://t.co/kqlXBlmYpu
Eric Topol EricTopol ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×